Acceleron Pharma Inc. (NASDAQ:XLRN) EVP Matthew L. Sherman sold 18,400 shares of Acceleron Pharma stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total transaction of $706,744.00. Following the transaction, the executive vice president now owns 79,750 shares in the company, valued at approximately $3,063,197.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Acceleron Pharma Inc. (NASDAQ XLRN) traded up 0.50% during trading on Thursday, reaching $39.94. 465,608 shares of the company’s stock were exchanged. The firm’s market capitalization is $1.55 billion. The company has a 50 day moving average of $35.47 and a 200 day moving average of $30.78. Acceleron Pharma Inc. has a 52-week low of $23.07 and a 52-week high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.12). The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.69 million. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. Acceleron Pharma’s revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.59) earnings per share. Equities analysts anticipate that Acceleron Pharma Inc. will post ($2.70) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/acceleron-pharma-inc-xlrn-evp-sells-706744-00-in-stock.html.

Several research firms recently weighed in on XLRN. Royal Bank Of Canada began coverage on shares of Acceleron Pharma in a report on Thursday. They set a “sector perform” rating on the stock. UBS AG restated a “buy” rating and set a $50.00 target price (up previously from $36.00) on shares of Acceleron Pharma in a report on Tuesday. BidaskClub upgraded shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 6th. Zacks Investment Research upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Thursday, July 13th. Finally, Credit Suisse Group set a $35.00 target price on shares of Acceleron Pharma and gave the company a “buy” rating in a report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $42.21.

Several large investors have recently added to or reduced their stakes in XLRN. Teachers Advisors LLC lifted its holdings in shares of Acceleron Pharma by 3.0% during the 4th quarter. Teachers Advisors LLC now owns 45,138 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 1,296 shares during the period. Bank of Montreal Can bought a new position in shares of Acceleron Pharma during the 1st quarter worth about $237,000. Nationwide Fund Advisors lifted its holdings in shares of Acceleron Pharma by 10.5% during the 1st quarter. Nationwide Fund Advisors now owns 22,737 shares of the biopharmaceutical company’s stock worth $602,000 after acquiring an additional 2,168 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Acceleron Pharma by 88.9% during the 1st quarter. Russell Investments Group Ltd. now owns 27,850 shares of the biopharmaceutical company’s stock worth $737,000 after acquiring an additional 13,108 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Acceleron Pharma by 106.1% during the 1st quarter. Wells Fargo & Company MN now owns 79,462 shares of the biopharmaceutical company’s stock worth $2,104,000 after acquiring an additional 40,910 shares during the period. 88.07% of the stock is owned by institutional investors.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.